AbbVie Lowers Full-Year EPS Guidance by $0.17 Due to Q2 IPR&D Expenses
ABBV sits 38% above its 52-week low of $184.63.
Summary
AbbVie updated its 2026 full-year and Q2 adjusted diluted EPS guidance, lowering it by $0.17 per share due to acquired IPR&D and milestones expenses incurred in the second quarter.
Key Events · Earnings and Guidance · ABBV
-
Revised Full-Year EPS Guidance
AbbVie's full-year 2026 adjusted diluted EPS guidance range is now $13.91 - $14.11, down from the previously announced $14.08 - $14.28.
-
Q2 IPR&D and Milestones Expense
The company expects to include $291 million in acquired IPR&D and milestones expense for the second quarter of 2026, representing an unfavorable impact of $0.17 per share.
-
Updated Q2 EPS Guidance
The second-quarter 2026 adjusted diluted EPS guidance range, including the IPR&D impact, is $3.57 - $3.61.
Analysis · ABBV · Life Sciences
AbbVie has revised its full-year and second-quarter adjusted diluted EPS guidance downwards due to $291 million in acquired IPR&D and milestones expense. This reduction, while stemming from R&D investments, directly impacts near-term profitability expectations and follows the recent announcement of the Apogee Therapeutics acquisition, which could be a source of such expenses. Investors will be watching how these expenses affect future earnings and the company's overall financial outlook.
At the time of this filing, ABBV was trading at $255.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $450.1B. The 52-week trading range was $184.63 to $261.64. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.